×

ImmunoGen CEO: Toxicity is a normal course for drug development

6:45 PM ET Wed, 14 Aug 2013

ImmunoGen president and CEO Daniel Junius discusses the potential for its cancer treatment Kadcyla, and whether investors should be concerned about toxicity problems in some of its drug trials.